Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2018, provides an overview of the Diabetic Gastroparesis (Gastrointestinal) pipeline landscape.
Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Gastroparesis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Gastroparesis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 3 and 2 respectively.
Diabetic Gastroparesis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Gastroparesis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Gastroparesis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Gastroparesis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Gastroparesis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Diabetic Gastroparesis - Pipeline Review, H1 2018
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Gastroparesis - Overview
Diabetic Gastroparesis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Diabetic Gastroparesis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Gastroparesis - Companies Involved in Therapeutics Development
Allergan Plc
ETX Pharma Inc
Evoke Pharma Inc
Johnson & Johnson
Melinta Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Theravance Biopharma Inc
Diabetic Gastroparesis - Drug Profiles
CEM-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metoclopramide hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prucalopride succinate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
renzapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-906 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAK-954 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
velusetrag hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Gastroparesis - Dormant Projects
Diabetic Gastroparesis - Discontinued Products
Diabetic Gastroparesis - Product Development Milestones
Featured News & Press Releases
Oct 27, 2017: Evoke Pharma Announces Conference Call to Review the Successful Results of Comparative Exposure Pharmacokinetic Study for Gimoti
Oct 23, 2017: Evoke Pharma Announces Positive Topline Results from Comparative Exposure Pharmacokinetic Study for Gimoti
Oct 04, 2017: Evoke Pharma to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference
Sep 12, 2017: Evoke Pharma Completes Dosing for Gimoti Comparative Exposure Pharmacokinetic Study
Sep 05, 2017: Evoke Pharma to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
Aug 14, 2017: Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti
Aug 09, 2017: EndoLogic Announces Feedback from Positive FDA Meeting for Renzapride in Diabetic Gastroparesis
May 31, 2017: Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti
May 15, 2017: Evoke Pharma Provides Update on Gimoti
May 10, 2017: Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017
May 03, 2017: EndoLogic Announces Scheduling of pre-IND Meeting with FDA to Discuss Renzapride in Diabetic Gastroparesis
May 01, 2017: Allergan to Present Data on Relamorelin at Digestive Disease Week 2017
Apr 04, 2017: Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA
Mar 21, 2017: Evoke Pharmas Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017
Jan 04, 2017: Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diabetic Gastroparesis, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Diabetic Gastroparesis - Pipeline by Allergan Plc, H1 2018
Diabetic Gastroparesis - Pipeline by ETX Pharma Inc, H1 2018
Diabetic Gastroparesis - Pipeline by Evoke Pharma Inc, H1 2018
Diabetic Gastroparesis - Pipeline by Johnson & Johnson, H1 2018
Diabetic Gastroparesis - Pipeline by Melinta Therapeutics Inc, H1 2018
Diabetic Gastroparesis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
Diabetic Gastroparesis - Pipeline by Theravance Biopharma Inc, H1 2018
Diabetic Gastroparesis - Dormant Projects, H1 2018
Diabetic Gastroparesis - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Diabetic Gastroparesis, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
Global Glycated Albumin Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 115
According to our LPI (LP Information) latest study, the global Glycated Albumin market size was valued at US$ 419.7 million in 2023. With growing demand in downstream market, the Glycated Albumin is forecast to a readjusted size of US$ 593.8 million by 2030 with a CAGR of 5.1% during review period.
The research report highlights the growth potential of the global Glycated Albumin market. Glycated Albumin are expected to show stable growth in the future market. However, product differenti......
Global Neuropathy Pain Treatment Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 88
According to our LPI (LP Information) latest study, the global Neuropathy Pain Treatment market size was valued at US$ 8341.5 million in 2023. With growing demand in downstream market, the Neuropathy Pain Treatment is forecast to a readjusted size of US$ 10560 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Neuropathy Pain Treatment market. Neuropathy Pain Treatment are expected to show stable growth in the futur......
Global Neuropathy Pain Treatment Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 92
According to our (Global Info Research) latest study, the global Neuropathy Pain Treatment market size was valued at USD 8773.9 million in 2023 and is forecast to a readjusted size of USD 10910 million by 2030 with a CAGR of 3.2% during review period.
This report studies the Neuropathy Pain Treatment market,
Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system. Neuropathy Pain Treatment is used for Neuropathic pain.
Global Neuropath......
Global Type 1 Diabetes Therapeutics Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 28-Dec-2023 Price: US 3380 Onwards Pages: 106
Market Overview of Global Type 1 Diabetes Therapeutics market:
According to our latest research, the global Type 1 Diabetes Therapeutics market looks promising in the next 5 years. As of 2022, the global Type 1 Diabetes Therapeutics market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in w......
Global Diabetic Neuropathy Professional Survey Report 2023, Forecast to 2028
Published: 26-Dec-2023 Price: US 3280 Onwards Pages: 104
Diabetic neuropathy is a type of nerve damage that can occur if you have diabetes.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are com......
Global Diabetic Neuropathy Market Research Report 2023, Forecast to 2028
Published: 26-Dec-2023 Price: US 2680 Onwards Pages: 132
Diabetic neuropathy is a type of nerve damage that can occur if you have diabetes.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are com......
Global Diabetic Nephropathy Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 23-Nov-2023 Price: US 3380 Onwards Pages: 122
Market Overview of Global Diabetic Nephropathy market:
According to our latest research, the global Diabetic Nephropathy market looks promising in the next 5 years. As of 2022, the global Diabetic Nephropathy market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
Diabetic nephropathy (DN) is a chronic loss of renal function in diabetic patients.
This report covers a research ti......
Global Glycated Albumin Market Research Report 2023, Forecast to 2028
Published: 21-Nov-2023 Price: US 2680 Onwards Pages: 166
Glycated albumin is albumin that has been glycated (bound to sugar). Albumin is the most common type of protein found in blood (~80% of circulating proteins) and is replaced in the body about every 20-25 days.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while ......
Global Glycated Albumin Professional Survey Report 2023, Forecast to 2028
Published: 21-Nov-2023 Price: US 3280 Onwards Pages: 106
Glycated albumin is albumin that has been glycated (bound to sugar). Albumin is the most common type of protein found in blood (~80% of circulating proteins) and is replaced in the body about every 20-25 days.
Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while ......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
